Glenmark receives FDA approval for Olopatadine Hydrochloride Ophthalmic Solution, competing with Alcon

From Nasdaq: 2025-03-20 23:58:00

Glenmark Pharmaceuticals Inc., USA has received final FDA approval for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), deemed bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC) by Alcon Laboratories Inc. The product will be distributed in the U.S. by Glenmark Therapeutics Inc., USA. Nielsen data shows the Pataday market generated around $50.7 million in sales for the latest 52-week period ending in February 2025. For more health news, visit rttnews.com.



Read more at Nasdaq: Glenmark Gets FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)